Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares

Rhea-AI Filing Summary

Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.

The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 3,261 shares ($74,416)

Net Sell 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Sold 3,261 shs ($74K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,261	$22.82	$74K

Holdings After Transaction: Common Stock — 223,640.175 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S		3,261(1)	D	$22.82	223,640.175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pacira BioSciences (PCRX) disclose about Jonathan Slonin’s recent stock transaction?

Pacira BioSciences reported that Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock at $22.82 per share on March 17, 2026. Following this open-market sale, he continues to hold 223,640.175 shares directly.

How many Pacira (PCRX) shares does the CMO still own after the March 2026 sale?

After selling 3,261 shares at $22.82 per share, Chief Medical Officer Jonathan Slonin directly owns 223,640.175 Pacira common shares. This filing shows he retained a substantial position in the company following the transaction.

Was the Pacira (PCRX) CMO’s March 2026 stock sale under a Rule 10b5-1 plan?

Yes. The filing states the 3,261-share sale at $22.82 per share was executed under a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, reducing the significance of short-term market timing.

What type of transaction did Pacira (PCRX) report for its CMO in March 2026?

Pacira reported an open-market sale of 3,261 shares of common stock by Chief Medical Officer Jonathan Slonin at $22.82 per share. The transaction is classified as a non-derivative sale, with shares held directly both before and after.

Does the Pacira (PCRX) Form 4 show any option exercises or derivative trades by the CMO?

No. The Form 4 only reports a non-derivative sale of 3,261 common shares at $22.82 per share. The derivative section is empty, indicating no option exercises or other derivative transactions in this particular filing.